ArticleJournal of neurology2020
Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications.
Article in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Brain connectivity changes underlying depression and fatigue in relapsing-remitting multiple sclerosis: A systematic review.PloS one · 2024Pooled it
- Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine.Journal of neurology · 2023Trial
- MRI Correlates of Depression and Anxiety in Multiple Sclerosis.Diseases (Basel, Switzerland) · 2026Review
- Functional and effective connectivity disruptions of the dopaminergic reward circuit in multiple sclerosis patients with depression.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- Reverse engineering of motor unit discharge in multiple sclerosis reveals heterogeneity of voluntary motor commands.medRxiv : the preprint server for health sciences · 2026Article
- Gray matter sodium accumulation and atrophy in relapsing-remitting multiple sclerosis correspond to neurotransmitter maps.European radiology · 2026Article
- Bodily experiences in multiple sclerosis: functional neurological symptoms, body image dissatisfaction, and disordered eating behaviors. A narrative review.Frontiers in psychology · 2026Review
- Pathophysiology of voluntary motor commands at the level of the spinal motoneuron in patients with multiple sclerosis.medRxiv : the preprint server for health sciences · 2025Article
- Regenerating Locus Coeruleus-Norepinephrine (LC-NE) Function: A Novel Approach for Neurodegenerative Diseases.Cell proliferation · 2025Review
- Identifying neuropsychological phenotypes in multiple sclerosis using latent profile analysis.European journal of neurology · 2025Article
- Depression and anxiety in multiple sclerosis. Review of a fatal combination.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation.Journal of neurology · 2024Article
- Chemogenetic activation of locus coeruleus neurons ameliorates the severity of multiple sclerosis.Journal of neuroinflammation · 2023Article
- Correspondence among gray matter atrophy and atlas-based neurotransmitter maps is clinically relevant in multiple sclerosis.Molecular psychiatry · 2023Article
- Graph-Based Analysis of Brain Connectivity in Multiple Sclerosis Using Functional MRI: A Systematic Review.Brain sciences · 2023Review
- Differences in resting state functional connectivity relative to multiple sclerosis and impaired information processing speed.Frontiers in neurology · 2023Article
- Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?International journal of molecular sciences · 2021Review
- Relapsing and progressive MS: the sex-specific perspective.Therapeutic advances in neurological disorders · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
There is mounting evidence regarding the role of impairment in neuromodulatory networks for neurodegenerative diseases, such as Parkinson's and Alzheimer's disease. However, the role of neuromodulatory networks in multiple sclerosis (MS) has not been assessed. We applied resting-state functional connectivity and graph theory to investigate the changes in the functional connectivity within neuromodulatory networks including the serotonergic, noradrenergic, cholinergic, and dopaminergic systems in MS. Twenty-nine MS patients and twenty-four age- and gender-matched healthy controls performed clinical and cognitive assessments including the expanded disability status score, symbol digit modalities test, and Hamilton Depression rating scale. We demonstrated a diffuse reorganization of network topography (P < 0.01) in serotonergic, cholinergic, noradrenergic, and dopaminergic networks in patients with MS. Serotonergic, noradrenergic, and cholinergic network functional connectivity derangement was associated with disease duration, EDSS, and depressive symptoms (P < 0.01). Derangements in serotonergic, noradrenergic, cholinergic, and dopaminergic network impairment were associated with cognitive abilities (P < 0.01). Our results indicate that functional connectivity changes within neuromodulatory networks might be a useful tool in predicting disability burden over time, and could serve as a surrogate endpoint to assess efficacy for symptomatic treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.